← Back to Trial
A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Trial Locations
-
Novartis
East Hanover, New Jersey, United States
- Contact: Novartis Pharmaceuticals · +41613241111 · [email protected] (opens in new tab)

